KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBITDA (2016 - 2025)

Medpace Holdings (MEDP) has disclosed EBITDA for 11 consecutive years, with $160.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 20.88% year-over-year to $160.2 million, compared with a TTM value of $562.1 million through Dec 2025, up 18.43%, and an annual FY2025 reading of $562.1 million, up 18.43% over the prior year.
  • EBITDA was $160.2 million for Q4 2025 at Medpace Holdings, up from $148.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $160.2 million in Q4 2025 and bottomed at $46.4 million in Q2 2021.
  • Average EBITDA over 5 years is $95.5 million, with a median of $91.4 million recorded in 2023.
  • The sharpest move saw EBITDA grew 0.89% in 2021, then skyrocketed 43.29% in 2022.
  • Year by year, EBITDA stood at $59.0 million in 2021, then skyrocketed by 38.03% to $81.5 million in 2022, then increased by 15.03% to $93.7 million in 2023, then soared by 41.36% to $132.5 million in 2024, then increased by 20.88% to $160.2 million in 2025.
  • Business Quant data shows EBITDA for MEDP at $160.2 million in Q4 2025, $148.6 million in Q3 2025, and $133.1 million in Q2 2025.